• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

    10/29/25 8:35:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLTE alert in real time by email

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hao-Yuan Chuang, Chief Financial Officer, will present live at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com, on November 4th, 2025. This virtual conference program is aimed exclusively at introducing global companies with ADR programs to investors.

    DATE: November 4th

    TIME: 10:30 am

    LINK: REGISTER HERE

    This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

    It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.  

    Participation is free of charge.

    About Belite Bio

    Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    CONTACTS:

    Belite Media and Investor Relations Contact:

    Jennifer Wu

    [email protected]

    Julie Fallon

    [email protected]

    Virtual Investor Conferences

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE

    DatePrice TargetRatingAnalyst
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    11/20/2025$105.00Neutral
    Mizuho
    12/14/2023$60.00Buy
    Maxim Group
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    7/26/2023$25.00Outperform
    SVB Securities
    8/1/2022$58.00Buy
    H.C. Wainwright
    More analyst ratings

    $BLTE
    SEC Filings

    View All

    SEC Form 424B5 filed by Belite Bio Inc

    424B5 - BELITE BIO, INC (0001889109) (Filer)

    12/2/25 4:03:32 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    12/2/25 4:00:42 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Belite Bio Inc

    424B5 - BELITE BIO, INC (0001889109) (Filer)

    12/1/25 5:12:13 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

    SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the Company at the public offering price, less underwriting discounts and commissions. The gross proceeds

    12/1/25 10:37:00 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

    SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addition, Belite Bio intends to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price, less underwriting discounts and commission. The offering is subject t

    12/1/25 4:20:00 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Belite Bio with a new price target

    Cantor Fitzgerald resumed coverage of Belite Bio with a rating of Overweight and set a new price target of $154.00

    11/24/25 8:35:36 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Belite Bio with a new price target

    Mizuho initiated coverage of Belite Bio with a rating of Neutral and set a new price target of $105.00

    11/20/25 8:06:38 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Leadership Updates

    Live Leadership Updates

    View All

    Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

    Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar

    9/1/24 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 9:08:25 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 8:40:46 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/15/23 1:36:20 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Financials

    Live finance-specific insights

    View All

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

    Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,

    11/12/24 1:00:25 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

    Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET

    11/13/23 8:15:47 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care